Buy Invokana

Invokana

What is Invokana?

Invokana is a brand-name medication that contains the active ingredient canagliflozin. It belongs to the therapeutic class of diabetes management drugs and is supplied as a 100 mg oral pill. In Hong Kong, Invokana is a prescription-only product regulated by the Department of Health’s Drug Office. The medication works by helping the kidneys remove excess glucose from the bloodstream, thereby lowering blood sugar levels in adults with type 2 diabetes mellitus.

How Invokana Works in the Body

Canagliflozin is a selective sodium-glucose co-transporter-2 (SGLT2) inhibitor. Under normal conditions, SGLT2 proteins in the proximal renal tubules reabsorb about 90 % of filtered glucose back into the circulation. By blocking this transporter, canagliflozin reduces glucose reabsorption, leading to:

• Increased urinary glucose excretion (typically 30-80 g per day)
• Lowered plasma glucose concentrations
• Modest reductions in body weight and systolic blood pressure due to osmotic diuresis

The onset of glucose-lowering effect occurs within 24 hours of the first dose, with a steady-state effect reached after 4-5 days of daily dosing. Canagliflozin is metabolized primarily via O-glucuronidation and is excreted unchanged in the urine and feces.

Conditions Treated by Invokana

Invokana is approved in Hong Kong for the following indication:

• Adjunctive therapy to diet and exercise in adults with type 2 diabetes mellitus when additional glycaemic control is needed.

It may be prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin, depending on the patient’s overall treatment plan.

Evidence-Based Off-Label Uses

Research studies have explored additional benefits of canagliflozin beyond glycaemic control:

• Chronic Kidney Disease (CKD): The CREDENCE trial demonstrated that canagliflozin 100 mg daily slowed the progression of diabetic kidney disease in patients with established CKD. This indication is not approved for Invokana in Hong Kong.
• Cardiovascular Risk Reduction: The CANVAS Program showed a reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients treated with canagliflozin. While promising, cardiovascular protection remains an off-label benefit in Hong Kong.

Off-label use requires medical supervision and individualized risk assessment. Healthcare providers must weigh the potential benefits against safety considerations before prescribing Invokana for CKD or cardiovascular protection.

Who Should (Not) Use Invokana?

Ideal candidates

• Adults with type 2 diabetes who need additional glucose lowering despite diet, exercise, and other oral agents.
• Patients with an eGFR ≥ 30 mL/min/1.73 m² (the lowest renal function level at which canagliflozin remains effective).

Absolute contraindications

• Known hypersensitivity to canagliflozin or any component of the tablet.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or patients on dialysis.
• Individuals with a history of diabetic ketoacidosis (DKA).

Relative contraindications & special populations

• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²): dose adjustment and close monitoring are required.
• Elderly patients: increased risk of volume depletion; monitor blood pressure and renal function.
• Pregnancy & lactation: canagliflozin is not recommended; limited data suggest potential fetal risk.
• Pediatric use: not approved for patients under 18 years of age.

If any of these conditions apply, clinicians should evaluate alternative therapies.

Safety Profile and Interactions

Common Side Effects

• Genital mycotic infections (e.g., candidal infections) - more frequent in females.
• Urinary tract infections - typically mild and self-limiting.
• Increased urination (polyuria) - due to osmotic diuresis.
• Mild hypotension - especially in patients also taking diuretics.

Serious Adverse Events

• Ketoacidosis (including euglycaemic DKA) - requires immediate medical attention.
• Acute kidney injury - monitor serum creatinine after initiation, especially in volume-depleted patients.
• Amputation risk (noted in some studies) - watch for signs of foot or toe ulcers.

Drug Interactions

• Insulin or sulfonylureas: May increase hypoglycaemia risk; dose reduction of the latter may be needed.
• Diuretics (loop or thiazide): Additive volume-depleting effect; monitor electrolytes and blood pressure.
• Rifampin or other strong CYP3A4 inducers: Can reduce canagliflozin exposure; consider alternative therapy.
• Strong CYP3A4 inhibitors (e.g., ketoconazole) and UGT1A9 inhibitors: May increase canagliflozin levels; adjust dose if clinically indicated.

Food and Lifestyle Interactions

• No specific food restrictions, but adequate hydration is advisable to reduce the risk of renal impairment and hypotension.
• Alcohol can potentiate hypoglycaemia when combined with insulin or sulfonylureas; patients should consume alcohol in moderation.
• Driving or operating machinery is generally safe, but patients experiencing dizziness should exercise caution.

If patients are unsure about potential interactions, they should provide a complete medication list-including over-the-counter products and herbal supplements-to their healthcare provider before starting Invokana.

How to Take Invokana

• Standard dosing: One 100 mg tablet taken once daily in the morning, with or without food.
• Renal adjustment: For eGFR 30-45 mL/min/1.73 m², the same 100 mg dose may be used with close monitoring; initiation below this range is contraindicated.
• Special populations: No routine dose reduction for elderly patients, but clinicians may consider starting at a lower dose if dehydration risk is high.
• Administration: Swallow the tablet whole; do not crush or chew.
• Missed dose: Take the missed tablet as soon as remembered on the same day; do not take a double dose the next day.
• Overdose: Symptoms may include severe dehydration, low blood pressure, or acute kidney injury. Seek emergency medical care; there is no specific antidote, and treatment is supportive.
• Discontinuation: Gradual tapering is not required, but patients should be monitored for rebound hyperglycaemia after stopping therapy.

Monitoring and Follow-Up

• Renal function: Serum creatinine and eGFR at baseline, then periodically (e.g., every 3-6 months) or after any acute illness.
• Blood glucose: HbA1c every 3 months to assess glycaemic control.
• Electrolytes: Particularly sodium and potassium if combined with diuretics.
• Signs of ketoacidosis: Educate patients to report nausea, vomiting, abdominal pain, or unexplained fatigue.
• Foot examination: Routine checks for ulceration, especially in patients with peripheral vascular disease.

Storage and Handling

• Store Invokana tablets at room temperature (≤ 30 °C/86 °F), away from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiration date printed on the packaging.
• Dispose of unused tablets according to local pharmacy take-back programmes or Hong Kong’s Household Waste Management guidelines.

Medication-Specific Glossary

SGLT2 Inhibitor

A class of drugs that block the sodium-glucose co-transporter-2 in the kidneys, reducing glucose reabsorption and promoting its excretion in urine.

eGFR (Estimated Glomerular Filtration Rate)

A calculated measure of kidney function used to adjust dosing of renally cleared medications such as canagliflozin.

Euglycaemic Diabetic Ketoacidosis

A rare form of ketoacidosis where blood glucose levels are not markedly elevated, often linked to SGLT2 inhibitor therapy.

Medical Disclaimer

This article provides educational information about Invokana and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.